527-07-1
CAS 527-07-1
527-07-1 (CAS 527-07-1) is a pharmaceutical compound with 1 bioactivity target and 2 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 22434.533333333336 nM | 3 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| SODIUM GLUCONATE | 56476 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 527-07-1 used for in pharmaceutical contexts?
527-07-1 (CAS 527-07-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 527-07-1?
527-07-1 has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Crohn's disease. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 527-07-1 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Gluconate with EU status "permitted".
What clinical phase is 527-07-1 in?
No phase 1-4 clinical development badge is rendered for 527-07-1 because the matched compound identifier rows do not contain a max-phase value.